Impact of Previous Treatment of HCV Patients by DAADs on Covid-19 Disease Frequency and Severity

• Conditions: Covid19
• Interventions: Drug: DAAD Compound

• Registration Number: NCT04729153
• Lead Sponsor: Assiut University

Brief Summary

Evaluate effect of DAADs on covid-19 disease.

Detailed Description

If Chronic HCV patients who already received DAADs are protected against covid 19 and considered to be immune or not And if DAADS can be used in ttt of covid 19

Study Timeline

• Status Verified: 2021-01
• Study First Submitted: 2021-01-23
• Study First Submitted QC: 2021-01-26
• Study First Posted: 2021-01-28
• Last Update Submitted: 2021-01-30
• Study Start: 2021-02
• Last Update Posted: 2021-02-03
• Primary Completion: 2022-02
• Study Completion: 2022-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. HCV patient with or without LC.
2. >18 years old.
3. Received DAADs at 2019.

Exclusion Criteria

1. Combined HCV and HIV infected patients.
2. Combined HCV and HBV infected patients.
3. < 18 years old.
4. Pregnant or breast-feeding patients.
5. Patients with autoimmune disease.
6. Patients with multiorgan failure, active cancer, renal insufficiency.
7. Patients received immunosuppressive drugs.
8. Immune compromised patients.
9. Previous confirmed diagnosis of SARS-CoV-2 before starting DAAs.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Chronic HCV patients previously treated by DAADs.	DAAD Compound	-

Primary Outcome Measures

Name	Time	Method
Evaluate the effect of DAADs on covid -19	12 months (from 1/2/2021 to 1/2/2022)	If chronic HCV patients who received DAADs suspected to be infected by covid-19 by having findings suggest covid 19 infection in MSCT chest or clinically symptoms or confirmed by nasopharyngeal swab . And if infected what about severity , if they need hospital admission or oxygen therapy or mechanical ventilation ,if they still alive or died